Lipella Pharmaceuticals announces U.S. patent issuance for diagnostic tech
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 17 2025
0mins
Should l Buy ?
Patent Issuance: Lipella Pharmaceuticals has been granted U.S. Patent No. 12,326,492 for a method of detecting interstitial cystitis using magnetic resonance imaging, effective until at least 2045.
Potential Applications: The patented method aims to improve outcome assessments in the company's development programs for mucosal disorders, including treatments for oral lichen planus, hemorrhagic cystitis, and bladder cancer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
